Be a part of 7th International Conference on Cancer Therapy

Cancer Biology and Translational Oncology: Molecular mechanisms of tumor development, tumor microenvironment, cancer signaling, biomarkers, translational research, and bench-to-bedside discoveries.
Precision Oncology, Cancer Genomics and Personalized Medicine: Genomic profiling, molecular classification, precision treatment selection, companion diagnostics, pharmacogenomics, and individualized cancer care.
Emerging Cancer Therapeutics and Novel Drug Development: Next-generation anticancer drugs, targeted therapies, antibody-drug conjugates, bispecific antibodies, novel drug targets, combination therapies, and clinical development.
Cancer Immunotherapy and Immune-Based Therapies: Immune checkpoint inhibitors, cancer vaccines, immune biomarkers, tumor immune microenvironment, combination immunotherapy, resistance mechanisms, and next-generation immune therapies.
Cell and Gene Therapy in Cancer: CAR-T and T-cell therapies, TCR therapies, engineered immune cells, gene editing, stem-cell approaches, safety challenges, treatment resistance, and next-generation cellular therapies.
Cancer Metastasis, Tumor Microenvironment and Disease Progression: Mechanisms of invasion and metastasis, circulating tumor cells, tumor–immune interactions, metastatic niches, therapy resistance, and strategies for controlling advanced disease.
Liquid Biopsy, Biomarkers and Molecular Diagnostics: Circulating tumor DNA, circulating tumor cells, early detection, minimal residual disease, treatment monitoring, molecular biomarkers, and real-time assessment of therapeutic response.
Artificial Intelligence, Digital Oncology and Precision Cancer Care: AI-assisted diagnosis, machine learning, predictive analytics, digital pathology, clinical decision support, radiomics, computational oncology, and personalized treatment planning.
Cancer Imaging, Radiomics and Advanced Radiation Oncology: Multimodal imaging, PET/CT, MRI, radiomics, image-guided therapy, adaptive radiotherapy, stereotactic techniques, proton therapy, and AI-enabled radiation planning.
Cancer Nanomedicine and Targeted Drug Delivery: Nanoparticles, nanocarriers, tumor-targeted delivery, theranostics, nanotechnology-enabled diagnostics, controlled drug release, and applications of nanomedicine in precision oncology.
Cancer Prevention, Early Detection, Screening and Survivorship: Risk reduction, screening strategies, early diagnosis, hereditary cancer prevention, lifestyle interventions, survivorship care, recurrence prevention, and long-term quality of life.
Global Oncology, Health Equity and Patient-Centered Cancer Care: Global disparities in cancer outcomes, access to innovative therapies, affordable cancer care, multidisciplinary oncology, patient-centered treatment, palliative care, survivorship, and international collaboration.

The global cancer research landscape is entering a period of accelerated innovation, driven by the growing cancer burden and rapid advances in precision medicine, immunotherapy, molecular diagnostics, and digital technologies. The latest IARC estimates indicate that 20.6 million people were diagnosed with cancer in 2024, with global cases projected to reach 34.4 million annually by 2050, highlighting the expanding need for effective prevention, early detection, and treatment strategies.

Research priorities are increasingly shifting toward precision oncology, AI-enabled cancer research, liquid biopsy, targeted therapies, cell and gene therapies, cancer vaccines, and novel drug development. AACR's 2026 research outlook identifies early detection, treatment personalization, immunotherapy, AI, and reducing disparities as major areas shaping the next generation of cancer research.

At the same time, significant opportunities remain in translating discoveries into accessible clinical applications. WHO reports that cancer clinical trials remain concentrated in high-income countries, while surgery, radiotherapy, diagnostics, and palliative care receive comparatively less research attention.

For Cancer Therapy 2027, these developments create strong opportunities for collaboration among academic researchers, oncologists, pharmaceutical and biotechnology companies, diagnostic organizations, technology providers, and healthcare institutions. The market is increasingly moving toward integrated, data-driven and patient-centered cancer care, making international knowledge exchange and multidisciplinary collaboration essential for converting scientific breakthroughs into improved outcomes.